Skip to main content
Premium Trial:

Request an Annual Quote

Gordon Foulkes, Mark Whitman, Michael Terry, GE Healthcare, Kreatech Biotechnology, Agilent, SuperArray Bioscience, BioSoft

Premium

Pairings

RiverVest Venture Partners this week said Gordon Foulkes has joined the firm as a venture partner. The venture capital firm invests in emerging medical technology and biopharmaceutical companies. Prior to joining RiverVest, Foulkes was chief scientific officer and member of the board of directors at OSI Pharmaceuticals, where he shepherded the initial development of Tarceva. Earlier, he served as chief technical officer and board member at Aurora Biosciences, now known as Vertex. Before that position, he was executive vice president of research and development, and a board member of Elitra Pharmaceuticals, where he headed efforts developing antimicrobial compounds from a functional genomics platform. He received his PhD in biochemistry from the University of Dundee, Scotland.


Mark Whitman has joined CombiMatrix Molecular Diagnostics as a member of its scientific advisory board and as a consultant in melanoma diagnosis and management. Whitman is the administrative director of surgical services and the director of the Melanoma Center at Mountainside Hospital, in Montclair, New Jersey. Prior to that position, he served as the director of the Melanoma Center of St. Louis. He graduated from Pennsylvania State University School of Medicine.


Michael Terry, executive vice president of sales and marketing at Sequenom entered into a separation agreement with the company on August 15, 2005, with a separation date of July 25, 2005, the firm said in a statement. Terry will provide "reasonable consulting services" in sales and marketing during the period he receives severance from Sequenom.

 

New Releases

GE Healthcare this week introduced its ECL Plex detection system for "simultaneous multi-wavelength" protein expression analysis on Western blots using Cy3 and Cy5 fluorescent dye labels, the company said in a statement. The system is designed for multipurpose imagers, rather than a specialized device, the company said. The ECL Plex provides "increased reproducibility and sensitivity" protein expression quantification, and uses direct fluorescence detection without enzyme substrate amplification, GE said. In the multiplex application, two proteins can be detected with minimal cross-reactivity between antibodies, the company added.


Kreatech Biotechnology this week launched its RNA ampULSe Amplification and Labeling Kits for DNA microarray applications.

The kit combines technology obtained from an agreement with Ambion for their MessageAmp II aRNA amplification system with Kreatech's Universal Linkage system labeling technology.

The company claims the kit will provide users with all the reagents necessary to go from total RNA samples to microarrays.


Agilent Technologies last week launched its Mouse Genome CGH Microarray 44A, which the company claims is the first mouse array specifically tailored for comparative genomic hybridization experiments.

According to Agilent, the Mouse Genome CGH array consists of 43,000, 60-mer oligo probes that provide coverage for the most commonly studied regions and cancer-related genes. Agilent said that it would be adding more organism-specific CGH arrays in the future.


SuperArray Bioscience last week launched GEArray Express, an array platform that is suitable for profiling the expression of focused sets of genes, according to the firm.

SuperArray also said that GEArray Express is capable up to 32 arrays a day and that "nearly 100 samples can be processed in 3 days at a cost of less than $100 per sample."


BioSoft International launched the fourth version of its Array Designer this week.

Array Designer is a desktop software tool that enables users to design oligos for their SNP and expression experiments, BioSoft said.

Filed under

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.